ReP USP - Resultado da busca

Filtros : "Hsia, Judith" Limpar

Filtros

Artigo de periodico
Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial (2023)
Hess, Connie N; Hsia, Judith; Carroll, Ian A; Nehler, Mark R; Ruf, Wolfram; Morrow, David A; Nicolau, Jose Carlos ; Berwanger, Otavio ; Szarek, Michael; Capell, Warren H
Source: Arteriosclerosis thrombosis and vascular biology. Unidade: FM
Subjects: COVID-19, ANTICOAGULANTES, HEMORRAGIA, FIBRINA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HESS, Connie N et al. Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial. Arteriosclerosis thrombosis and vascular biology, v. 43, n. 8, p. 1572-1582, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/56014. Acesso em: 09 nov. 2024.
APA
Hess, C. N., Hsia, J., Carroll, I. A., Nehler, M. R., Ruf, W., Morrow, D. A., et al. (2023). Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial. Arteriosclerosis thrombosis and vascular biology, 43( 8), 1572-1582. doi:10.1161/ATVBAHA.122.318748
NLM
Hess CN, Hsia J, Carroll IA, Nehler MR, Ruf W, Morrow DA, Nicolau JC, Berwanger O, Szarek M, Capell WH. Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial [Internet]. Arteriosclerosis thrombosis and vascular biology. 2023 ; 43( 8): 1572-1582.[citado 2024 nov. 09 ] Available from: https://observatorio.fm.usp.br/handle/OPI/56014
Vancouver
Hess CN, Hsia J, Carroll IA, Nehler MR, Ruf W, Morrow DA, Nicolau JC, Berwanger O, Szarek M, Capell WH. Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial [Internet]. Arteriosclerosis thrombosis and vascular biology. 2023 ; 43( 8): 1572-1582.[citado 2024 nov. 09 ] Available from: https://observatorio.fm.usp.br/handle/OPI/56014
Artigo de periodico
Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial (2022)
Hess, Connie N.; Capell, Warren H.; Bristow, Michael R.; Ruf, Wolfram; Szarek, Michael; Morrow, David A.; Nicolau, Jose Carlos ; Graybill, Christopher A.; Marshall, Debra; Hsia, Judith
Source: American heart journal. Unidade: FM
Subjects: COVID-19, TROMBOSE, REPLICAÇÃO VIRAL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HESS, Connie N. et al. Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial. American heart journal, v. 246, p. 136-143, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.ahj.2021.12.010. Acesso em: 09 nov. 2024.
APA
Hess, C. N., Capell, W. H., Bristow, M. R., Ruf, W., Szarek, M., Morrow, D. A., et al. (2022). Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial. American heart journal, 246, 136-143. doi:10.1016/j.ahj.2021.12.010
NLM
Hess CN, Capell WH, Bristow MR, Ruf W, Szarek M, Morrow DA, Nicolau JC, Graybill CA, Marshall D, Hsia J. Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial [Internet]. American heart journal. 2022 ; 246 136-143.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1016/j.ahj.2021.12.010
Vancouver
Hess CN, Capell WH, Bristow MR, Ruf W, Szarek M, Morrow DA, Nicolau JC, Graybill CA, Marshall D, Hsia J. Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial [Internet]. American heart journal. 2022 ; 246 136-143.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1016/j.ahj.2021.12.010

Digital Library of Intellectual Production of Universidade de São Paulo 2012 - 2024